Our Path

News & Press

Press ReleaseJune 19, 2026
Read more →

Polku Therapeutics Reports Positive Efficacy for Lead Compound POLK-38 in PS19 Tauopathy Model

Company to present new data from its PREP-targeting platform at the Alzheimer's Association International Conference (AAIC) 2026.

Press ReleaseOctober 9, 2025
Read more →

Polku Therapeutics' compound blocks memory loss after repeated mild traumatic brain injury in preclinical model

Preclinical data demonstrates disease-modifying potential of PREP PPI modulators beyond classical tauopathies, extending to traumatic brain injury models.

NewsJanuary 31, 2025
Read more →

Polku Therapeutics Secures Funding to Advance Disease-Modifying Therapies for Tauopathies

Funding from the Alzheimer's Association and Rainwater Charitable Foundation to support the advancement of tau-targeting therapies.

NewsOctober 16, 2024
Read more →

Polku Therapeutics Named VC Favorite at Health Design Pitch Competition

Recognized by venture capital judges as the standout company at the Health Design pitch competition.